Influence of Traditional Chinese Medicine on Medical Adherence and Outcome in Estrogen Receptor (+) Breast Cancer Patients in Taiwan: A Real-World Population-Based Cohort Study

被引:17
作者
Chan, Pi-Wei [1 ]
Chiu, Jen-Hwey [1 ,2 ,3 ]
Huang, Nicole [4 ]
Chen, Chyong-Mei [5 ]
Yu, Hung [6 ]
Liu, Chun-Yu [2 ,7 ,8 ]
Hsu, Chung-Hua [1 ,9 ]
机构
[1] Natl Yang Ming Univ, Sch Med, Inst Tradit Med, Taipei, Taiwan
[2] Taipei Vet Gen Hosp, Comprehens Breast Hlth Ctr, 201,Sec 2,Shih Pai Rd, Taipei 112, Taiwan
[3] Cheng Hsin Gen Hosp, Dept Surg, Div Gen Surg, Taipei, Taiwan
[4] Natl Yang Ming Univ, Inst Hosp & Hlth Care Adm, Sch Med, Taipei, Taiwan
[5] Natl Yang Ming Univ, Inst Publ Hlth, Taipei 11221, Taiwan
[6] MacKay Mem Hosp, Dept Pharm, Taipei, Taiwan
[7] Taipei Vet Gen Hosp, Dept Oncol, Div Med Oncol, 201,Sec 2,Shih Pai Rd, Taipei 112, Taiwan
[8] Natl Yang Ming Univ, Sch Med, 155,Sec 2,Li Nong St, Taipei 112, Taiwan
[9] Taipei City Hosp, Branch Linsen Chinese Med & Kunming, 530 Linsen North Rd, Taipei 104, Taiwan
关键词
Breast cancer; MPR; Medication adherence; Traditional Chinese medicine; Estrogen receptor; THERAPY; WOMEN; TAMOXIFEN; STAGE; ANASTROZOLE; PERSISTENCE; DIAGNOSIS;
D O I
10.1016/j.phymed.2020.153365
中图分类号
Q94 [植物学];
学科分类号
071001 ;
摘要
Background: Medical adherence is often higher in clinical trials than in real world practice. The aim of this study was to investigate the effects of traditional Chinese medicine (TCM) on medical adherence to hormonal therapy (HT) and survival outcome in ER (+) breast cancer patients in Taiwan. Subjects and methods: Using a nationwide longitudinal population-based database, we enrolled patients with newly diagnosed ER-positive breast cancer who had received HT, and followed for up to 5 years (N = 872). Medication adherence in terms of medication possession ratios (MPR) and patient outcome were evaluated with or without TCM exposure. We applied logistic regression and Cox proportional hazards (PH) analysis to identify factors, including TCM exposure, associated with adherence to HT and mortality. Results: MPR to HT in general decreased over the 5-year period post breast cancer diagnosis. Both TCM and MPR to HT >= 80% were significantly associated with reduced risk of breast cancer-associated mortality. Subgroup analysis revealed that TCM annual visits >= 3 times with CHP prescription 1 similar to 90 days per year affected mortality reduction most significantly (HR: 0.26; 95% CI = 0.08-0.83; p < 0.05) compared to other TCM use. In contrast, using TCM (either short-term or long-term) was not associated with MPR in HT. Conclusions: Our results supported the potential advantage of TCM on breast cancer-associated mortality, whereas TCM use does not compromise medical adherence to HT. This study offers important insights in integrative therapy for HT in patients with estrogen receptor (+) breast cancer.
引用
收藏
页数:8
相关论文
共 29 条
[1]   The use of Chinese herbal medicine to improve quality of life in women undergoing chemotherapy for ovarian cancer: a double-blind placebo-controlled randomized trial with immunological monitoring [J].
Chan, K. K. L. ;
Yao, T. J. ;
Jones, B. ;
Zhao, J. F. ;
Ma, F. K. ;
Leung, C. Y. ;
Lau, S. K. ;
Yip, M. W. ;
Ngan, H. Y. S. .
ANNALS OF ONCOLOGY, 2011, 22 (10) :2241-2249
[2]   In vivo and in vitro demonstration of herb-drug interference in human breast cancer cells treated with tamoxifen and trastuzumab [J].
Chen, Jiun-Liang ;
Wang, Jir-You ;
Tsai, Yi-Fang ;
Lin, Yi-Hsien ;
Tseng, Ling-Ming ;
Chang, Wen-Chi ;
King, Kuan-Liang ;
Chen, Wei-Shone ;
Chiu, Jen-Hwey ;
Shyr, Yi-Ming .
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2013, 20 (06) :646-654
[3]   Monitoring of immune responses to a herbal immuno-modulator in patients with advanced colorectal cancer [J].
Chen, X ;
Hu, ZP ;
Yang, XX ;
Huang, M ;
Gao, YH ;
Tang, WB ;
Chan, SY ;
Dai, XH ;
Ye, JX ;
Ho, PCL ;
Duan, W ;
Yang, HY ;
Zhu, YZ ;
Zhou, SF .
INTERNATIONAL IMMUNOPHARMACOLOGY, 2006, 6 (03) :499-508
[4]  
Cherbal Farid, 2015, Breast Dis, V35, P95, DOI 10.3233/BD-150398
[5]   In vitro and in vivo immunomodulating and immunorestorative effects of Astragalus membranaceus [J].
Cho, William Chi Shing ;
Leung, Kwok Nam .
JOURNAL OF ETHNOPHARMACOLOGY, 2007, 113 (01) :132-141
[6]   News from the 2007 San Antonio Breast Cancer Symposium [J].
Fricker, Janet .
MOLECULAR ONCOLOGY, 2008, 1 (04) :376-378
[7]   Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 [J].
Goldhirsch, A. ;
Winer, E. P. ;
Coates, A. S. ;
Gelber, R. D. ;
Piccart-Gebhart, M. ;
Thuerlimann, B. ;
Senn, H. -J. .
ANNALS OF ONCOLOGY, 2013, 24 (09) :2206-2223
[8]   Oldenlandia diffusa extracts exert antiproliferative and apoptotic effects on human breast cancer cells through ERα/Sp1-mediated p53 activation [J].
Gu, Guowei ;
Barone, Ines ;
Gelsomino, Luca ;
Giordano, Cinzia ;
Bonofiglio, Daniela ;
Statti, Giancarlo ;
Menichini, Francesco ;
Catalano, Stefania ;
Ando, Sebastiano .
JOURNAL OF CELLULAR PHYSIOLOGY, 2012, 227 (10) :3363-3372
[9]   Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer [J].
Hershman, Dawn L. ;
Shao, Theresa ;
Kushi, Lawrence H. ;
Buono, Donna ;
Tsai, Wei Yann ;
Fehrenbacher, Louis ;
Kwan, Marilyn ;
Gomez, Scarlett Lin ;
Neugut, Alfred I. .
BREAST CANCER RESEARCH AND TREATMENT, 2011, 126 (02) :529-537
[10]   Early discontinuation of tamoxifen intake in younger women with breast cancer: Is it time to rethink the way it is prescribed? [J].
Huiart, Laetitia ;
Bouhnik, Anne-Deborah ;
Rey, Dominique ;
Tarpin, Carole ;
Cluze, Camille ;
Bendiane, Marc Karim ;
Viens, Patrice ;
Giorgi, Roch .
EUROPEAN JOURNAL OF CANCER, 2012, 48 (13) :1939-1946